Biocon betting big on new product launches for growth

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrates development, production, distribution, and market deployment. Biocon Biologics has acquired Viatris' global biosimilars business, boosting revenue. The company is building a strong brand presence globally, especially in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c9rRp5L
via IFTTT